Biomoda Enters Final Stage of Patient Testing for Phase II Lung Cancer
Clinical Study
ALBUQUERQUE, N.M., Oct. 23 /PRNewswire-FirstCall/ -- Biomoda, Inc. (OTC
Bulletin Board: BMOD), a diagnostics company focused on the development of
accurate, inexpensive and noninvasive in-vitro tests for the early detection
of cancer, has met its recruitment goal for New Mexico veterans with a history
of heavy smoking required to complete the Phase II clinical trial of Biomoda's
early-stage diagnostic for lung cancer. The next stage of the Phase II trial
calls for Biomoda to begin testing samples from already-diagnosed lung cancer
patients in accordance with the study protocol approved by the U.S. Food and
Drug Administration (FDA).
"More than 500 veterans volunteered to be screened with the Biomoda assay. It
has been heartening to see so many men and women who served their country in
the armed forces willing to help once again by participating in this important
study," said John Cousins, President of Biomoda. "The study is not complete,
but we are pleased with the progress to date and expect to have final data in
the first half of 2010."
The Biomoda diagnostic, trademarked under the name CyPath®, is based on a
patented porphyrin-based compound that binds to cancer cells and fluoresces
red under ultraviolet light. Under the guidance of a respiratory therapist,
study volunteers provide a deep-lung sputum sample that is screened for cancer
cells with both the CyPath® assay and traditional Pap staining. Participants
also undergo a CT scan.
Dr. Thomas Bauer, chief of thoracic surgery at the Helen F. Graham Cancer
Center, Christiana Care Health System, in Delaware, is the Principal
Investigator overseeing the Phase II clinical trial. He has lead several lung
and esophageal cancer studies and heads up Christiana's participation in the
International Early Lung Cancer Action Program (I-ELCAP).
Based in Albuquerque, NM, Biomoda is a cancer diagnostics company focused on
the development of accurate, inexpensive and noninvasive in-vitro tests for
the early detection of cancer.
SOURCE Biomoda, Inc.
John Cousins, +1-505-821-0875, for Biomoda, Inc.
